BioAdaptives Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $18.3K | $12.7K | $28.6K | $17.2K | $19.8K | $16.3K | $9.9K |
| Cost of Revenue | — | $5.8K | $8.6K | $17.7K | $10.1K | $9.7K | $10.2K | $5.0K |
| Gross Profit | — | $12.5K | $4.0K | $10.8K | $7.1K | $10.1K | $6.1K | $4.9K |
| Gross Margin | — | 68.4% | 31.8% | 37.9% | 41.5% | 51.1% | 37.3% | 49.2% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | — | $820.5K | $335.3K | $101.5K | $254.1K | $268.3K | $72.4K | $88.9K |
| Operating Income | — | $-1.0M | $-602.1K | $-228.9K | $-421.9K | — | $-616.9K | $-39.6K |
| Operating Margin | — | -5,701.8% | -4,752.5% | -801.4% | -2,456.3% | — | -3,778.5% | -398.7% |
| Interest Expense | — | $70.9K | $92.0K | $162.9K | $289.1K | $272.4K | $230.3K | $199.3K |
| Pretax Income | — | $-1.6M | $-899.2K | — | — | — | $-847.2K | $-238.9K |
| Income Tax Expense | — | $0 | $0 | — | $0 | $0 | $0 | $0 |
| Net Income | — | $-1.6M | $-899.2K | $-712.5K | $-895.6K | $-1.0M | $-847.2K | $-238.9K |
| Net Margin | — | -8,523.4% | -7,097.3% | -2,494.2% | -5,214.1% | -5,309.2% | -5,189.2% | -2,405.1% |
| EPS (Basic) | — | — | $-0.11 | $-0.12 | — | — | $-0.04 | $-0.01 |
| EPS (Diluted) | — | $-0.15 | $-0.11 | — | — | — | $-0.04 | $-0.01 |
| Shares Outstanding (Basic) | 12.0M | — | 8.2M | 6.0M | 252.6M | 50.8M | 20.8M | 18.6M |
| Shares Outstanding (Diluted) | 12.0M | 10.1M | 8.2M | 6.0M | 252.6M | 50.8M | 20.8M | 18.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |